|View printer-friendly version|
Investigator-initiated clinical trial may follow preclinical studies
Scarring of the vocal folds is the most common cause of undesired changes in the voice (dysphonia) following injury, disease, or surgical procedures. Current treatments are limited to microsurgical treatments including scar lysis/excision, medialization laryngoplasty, or engraftment of tissue flaps/grafts. Since the region of the vocal fold affected by scarring is rich in hyaluronic acid, nonclinical studies of HyStem®-based hydrogels have been performed which indicate that localized injection of a HyStem® hydrogel during surgical release of the adhesions provides an environment for improved tissue viscoelasticity vital for vocal fold function. Because vocal fold scarring remains one of the most challenging problems for otolaryngologists using the available technology, continued successful preclinical studies could lead to investigator-initiated clinical investigations, and efforts for regulatory approval for this indication.
“If products could be developed that would improve vocal fold healing with decreased scarring, it could have widespread clinical application for improved patient outcomes,” said Dr. Remacle, at the Cliniques Universitaires UCL Mont-Godinne in
“The expanded application of HyStem® hydrogels in the field of vocal fold disorders, is just one example of the breadth of potential applications of the technology,” said Dr.
BioTime’s HyStem® family of hydrogels are unique biomaterials that are designed as matrices and scaffolds in medical device, tissue engineering, and regenerative medicine applications. HyStem® hydrogels are distributed and sold worldwide by
Asterias Biotherapeutics, Inc. is developing pluripotent stem-cell based therapies in neurology and oncology, including AST-OPC1 oligodendrocyte progenitor cells in spinal cord injury, multiple sclerosis and stroke, and AST-VAC2, an allogeneic dendritic cell-based cancer vaccine. Asterias Series A common stock is traded under the symbol ASTY.
- BioTime Asia, Ltd., a
Hong Kongcompany, may offer and sell products for research use for BioTime’s ESI BIO Division.
- Cell Cure Neurosciences Ltd. is an
Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis. ESI BIOis the research and product marketing division of BioTime, providing stem cell researchers with products and technologies to enable them to translate their work into the clinic, including PureStem® progenitors and HyStem® hydrogels.
- LifeMap Sciences, Inc. markets, sells, and distributes GeneCards®, the leading human gene database, as part of an integrated database suite that also includes the LifeMap Discovery® database of embryonic development, stem cell research, and regenerative medicine, and MalaCards, the human disease database.
- LifeMap Solutions, Inc. is a subsidiary of LifeMap Sciences focused on developing mobile health (mHealth) products.
- OncoCyte Corporation is developing products and technologies to diagnose and treat cancer, including PanC-Dx™, with three clinical trials currently underway.
- OrthoCyte Corporation is developing therapies to treat orthopedic disorders, diseases and injuries.
- ReCyte Therapeutics, Inc. is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology.
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for
To receive ongoing
Judith Segall, 510-521-3390, ext 301